Edition:
United Kingdom

CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

44.53USD
8:10pm BST
Change (% chg)

$-4.47 (-9.11%)
Prev Close
$48.99
Open
$47.05
Day's High
$47.25
Day's Low
$43.68
Volume
1,343,887
Avg. Vol
330,832
52-wk High
$73.90
52-wk Low
$16.17

Chart for

About

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct... (more)

Overall

Beta: --
Market Cap(Mil.): $783.42
Shares Outstanding(Mil.): 40.59
Dividend: --
Yield (%): --

Financials

  CRSP.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -0.07 -- --
ROI: -16.50 1.78 14.61
ROE: -56.05 3.27 16.33

CRISPR gene editing can cause risky collateral DNA damage: study

LONDON Scientists studying the effects of the potentially game-changing gene editing tool CRISPR/Cas9 have found it can cause unexpected genetic damage which could lead to dangerous changes in some cells.

16 Jul 2018

UPDATE 2-CRISPR gene editing can cause risky collateral DNA damage - study

LONDON, July 16 Scientists studying the effects of the potentially game-changing gene editing tool CRISPR/Cas9 have found it can cause unexpected genetic damage which could lead to dangerous changes in some cells.

16 Jul 2018

BRIEF-Crispr Therapeutics Reports Q1 Loss Per Share $0.62

* CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

08 May 2018

Competitors

Earnings vs. Estimates